Silence Therapeutics (SLN) Retained Earnings (2018 - 2026)
Silence Therapeutics (SLN) posted Retained Earnings of -$3.4 million for Q1 2026, up 99.4% sequentially from -$562.6 million in Q4 2025, and up 99.33% YoY from -$1.7 million in Q1 2025.
Silence Therapeutics (SLN) Retained Earnings (2018 - 2026) Analysis & Trends
Silence Therapeutics has reported Retained Earnings for 9 years, with the latest figure at -$3.4 million in Q1 2026.
- Quarterly Retained Earnings rose 99.33% year-over-year to -$3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.4 million (up 99.33% YoY) and the FY2025 annual result came in at -$562.6 million, down 4675.25% from the prior year.
- Retained Earnings improved to -$3.4 million in Q1 2026 per SLN's latest filing, from -$562.6 million in the prior quarter.
- Over five years, Retained Earnings peaked at -$3.4 million in Q1 2026 and troughed at -$562.6 million in Q4 2025.
- A 5-year average of -$356.0 million and a median of -$440.3 million in 2023 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2025 and 2026: Retained Earnings slumped 4675.25% in 2025, then soared 99.33% in 2026.
- Over 5 years, Retained Earnings stood at -$308.8 million in 2022, then declined by 22.43% to -$378.1 million in 2023, then jumped by 96.88% to -$11.8 million in 2024, then plunged by 4675.25% to -$562.6 million in 2025, then jumped by 99.4% to -$3.4 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$3.4 million, -$562.6 million, and -$550.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Silence Therapeutics | 648.22 Mn | 576.12 Mn | - | -589.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -589.63 Mn |
| Mar 31, 2026 | -3.37 Mn |
| Dec 31, 2025 | -562.57 Mn |
| Sep 30, 2025 | -550.80 Mn |
| Jun 30, 2025 | -529.80 Mn |
| Mar 31, 2025 | -502.50 Mn |
| Dec 31, 2024 | -11.78 Mn |
| Dec 31, 2023 | -378.05 Mn |
| Dec 31, 2022 | -308.79 Mn |
| Dec 31, 2021 | -300.56 Mn |
| Dec 31, 2020 | -243.25 Mn |
| Dec 31, 2019 | -195.43 Mn |
| Dec 31, 2018 | -172.14 Mn |